Clearmind Medicine Inc. announced positive safety findings from Part A of its FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate for Alcohol Use Disorder. The study enrolled 24 healthy volunteers across four ascending-dose cohorts (approximately 20 mg to 160 mg), all of whom completed treatment per protocol with no serious adverse events observed. This consistent tolerability profile supports the compound's advancement toward subsequent clinical stages, including dosing in AUD patients. Clearmind Medicine Inc. is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived therapeutics for addiction and weight management.

Clearmind Medicine Inc. filed a patent application with the Hong Kong Patent Office for novel psychedelic compounds targeting Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. This filing is part of its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. Clearmind's intellectual property portfolio currently consists of nineteen patent families and 32 granted patents. Clearmind Medicine Inc. is a clinical-stage biotechnology company focused on the discovery and development of non-hallucinogenic, neuroplastogen-derived therapeutics for addiction and mental health disorders.

Clearmind Medicine Inc. issued a press release on July 17, 2026, noting regulatory and inter-agency developments supporting psychedelic-based therapies. These developments include final FDA guidance on psychedelic clinical investigations, a planned public hearing, and new collaborative initiatives involving the U.S. Department of Health and Human Services, Department of Veterans Affairs, and FDA. Clearmind Medicine is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder, addiction, and weight management.

Clearmind Medicine Inc. reported positive ex vivo mucoadhesion results for its intranasal formulation of MEAI (5-Methoxy-2-aminoindane), demonstrating improved nasal residence time compared to a standard solution. The mucoadhesive polymer system in the new formulation aims to maximize MEAI absorption and therapeutic potential for treating Alcohol Use Disorder. Clearmind Medicine Inc. is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived treatments for addiction and weight management.

Clearmind Medicine Inc. released real-world insights from its ongoing CMND-100 first-in-human clinical trial on July 13, 2026. The company reported promising data regarding the investigational compound's performance in early human subjects. Clearmind Medicine is a biopharmaceutical company focused on developing psychedelic-based medicines for neurological and psychiatric disorders.

Clearmind Medicine Inc. issued a press release on July 10, 2026, regarding its response to a U.S. Administration Request for Information (RFI) concerning addiction treatment innovations under the Great American Recovery Initiative. The company is participating in this regulatory feedback process to address addiction treatment needs. Clearmind Medicine is a biopharmaceutical company focused on developing novel treatments for mental health disorders.